GlaxoSmithKline Pharmaceuticals has announced strong financial results for the year ended March 31, 2026, reporting a consolidated net profit of Rs 1,036 crore, up from Rs 928 crore in the previous year. The company’s revenue from operations for the fiscal reached Rs 3,822 crore. Additionally, the Board has recommended a final dividend of Rs 57 per equity share, subject to approval at the upcoming Annual General Meeting on June 30, 2026.
Annual Financial Performance
For the financial year ended March 31, 2026, GlaxoSmithKline Pharmaceuticals demonstrated robust growth. The company achieved a consolidated revenue of Rs 3,822 crore, compared to Rs 3,749 crore in the previous fiscal year. Consolidated net profit for the year rose to Rs 1,036 crore, reflecting a positive trajectory compared to the Rs 928 crore reported for the year ended March 31, 2025.
Dividend Recommendation
Demonstrating a commitment to shareholder value, the Board of Directors has recommended a final dividend of Rs 57 per equity share (face value of Rs 10 each). This dividend is subject to the approval of shareholders at the 101st Annual General Meeting, which is scheduled to be held on June 30, 2026. The record date for determining shareholder entitlement to this dividend has been fixed for May 29, 2026.
Quarterly Highlights
In the final quarter (Q4) ending March 31, 2026, the company reported revenue from operations of Rs 995 crore. The consolidated net profit for this quarter stood at Rs 278 crore, an increase from Rs 263 crore in the corresponding quarter of the previous year. The company continues to maintain a strong focus on its core pharmaceuticals business segment.
Source: BSE
